Breast cancer claims around 6,70,000 lives in a year. As per the data released by the World Health Organisation (WHO) breast cancer was the most common cancer in women in 157 countries out of 185 in 2022. Over 2 million women are diagnosed with breast cancer every year. This necessitates early diagnosis of the deadly disease and finding a drug targeting the cancerous cells.
The US Food and Drug Administration (FDA) has approved Kisqali for early stage breast treatment. The drug, also known as ribociclib, has been approved for use in combination with hormone therapy for early stage breast cancer patients. This will be helpful for those patients who have a concern over the return of cancer.
"The Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, FDA also approved the ribociclib and letrozole co-pack (Kisqali Femara Co-Pack, Novartis Pharmaceuticals Corporation) for the same indication," the US FDA said in an official statement.
Kisqali: How does it work?
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6), explains the manufacturer Novartis. These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably, it adds.
Kisqali: How will it be administered?
Kisqali will be administered as an oral pill. It will be prescribed for three weeks, with a one-week break, to be continued for three years.
It can be taken with or without food. A daily oral dose of 400 mg is recommended.
Kisqali: Side effects
The common side effects associated with Kisqali medicine are low white blood cell count or neutropenia. Neutropenia occurs when there are lower levels of neutrophils in the blood; neutrophils are essential to fight off infection in the body. Another side effect of Kisqali can be liver related issues and interstitial lung disease/ pneumonitis.
Video
The US Food and Drug Administration (FDA) has approved Kisqali for early stage breast treatment. The drug, also known as ribociclib, has been approved for use in combination with hormone therapy for early stage breast cancer patients. This will be helpful for those patients who have a concern over the return of cancer.
"The Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, FDA also approved the ribociclib and letrozole co-pack (Kisqali Femara Co-Pack, Novartis Pharmaceuticals Corporation) for the same indication," the US FDA said in an official statement.
Kisqali: How does it work?
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6), explains the manufacturer Novartis. These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably, it adds.
Kisqali: How will it be administered?
Kisqali will be administered as an oral pill. It will be prescribed for three weeks, with a one-week break, to be continued for three years.
It can be taken with or without food. A daily oral dose of 400 mg is recommended.
Kisqali: Side effects
The common side effects associated with Kisqali medicine are low white blood cell count or neutropenia. Neutropenia occurs when there are lower levels of neutrophils in the blood; neutrophils are essential to fight off infection in the body. Another side effect of Kisqali can be liver related issues and interstitial lung disease/ pneumonitis.
Video
You may also like
Mikel Arteta needs just one word to sum up David Raya after rescuing Arsenal
"This is new Ayodhya": UP CM Yogi announces Rs 1000 crore for Milkipur
"Won't tolerate disrespect": DK Suresh attacks BJP MLA Muniratna over his alleged casteist remark
Carly Gregg Unable To Control Her Giggles While Being Charged For Mother's Murder
